Vaccine Side Effects, also known as adverse events following immunization (AEFI), are potential reactions that may occur after receiving a vaccine. It's important to note that most vaccine side effects are mild and temporary, such as soreness at the injection site, low-grade fever, or mild fatigue. These reactions are typically short-lived and resolve on their own without any long-term consequences. However, vaccines, like any medical intervention, can occasionally cause more serious side effects, although these are rare. Severe allergic reactions, known as anaphylaxis, can occur shortly after vaccination but are extremely rare, occurring in approximately 1 in every million vaccine doses administered. Symptoms of anaphylaxis may include difficulty breathing, swelling of the face or throat, rapid heartbeat, and dizziness, and require immediate medical attention.
Other rare but serious side effects associated with specific vaccines include febrile seizures, Guillain-Barré Syndrome (GBS), and acute disseminated encephalomyelitis (ADEM). These adverse events are closely monitored by public health authorities and vaccine safety surveillance systems to detect any potential signals or patterns and ensure the ongoing safety of vaccines. It's essential to emphasize that the benefits of vaccination far outweigh the risks of potential side effects. Vaccines have been rigorously tested in clinical trials to ensure their safety and efficacy before being approved for use. Additionally, extensive post-marketing surveillance systems continuously monitor vaccine safety to detect and investigate any adverse events that may occur after vaccination. The vast majority of vaccine side effects are mild and transient, and the risk of serious adverse events is extremely low. The benefits of vaccination in preventing serious and potentially life-threatening diseases, reducing the spread of infectious pathogens, and protecting individuals and communities far outweigh the risk of adverse events.
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India